Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7853.007 | 1.0051 | 1.0076 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7853.007 | 0.9260 | 0.8881 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7853.007 | 0.8254 | 0.7322 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7853.007 | 0.4065 | 0.0191 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7853.007 | 0.0843 | -0.6863 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7853.007 | 0.0300 | -0.8552 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7853.007 | 0.1179 | -0.5967 | 1.3351 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10056.034 | 1.0158 | 1.0366 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10056.034 | 1.0161 | 1.0374 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10056.034 | 1.0334 | 1.0775 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10056.034 | 0.9922 | 0.9819 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10056.034 | 0.9819 | 0.9582 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10056.034 | 0.6558 | 0.2279 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10056.034 | 0.2090 | -0.6727 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10056.034 | 0.0610 | -0.9212 | 0.8648 | |
| HCC3153 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10056.034 | 0.0971 | -0.8651 | 0.8648 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9453.121 | 1.0016 | 1.0024 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9453.121 | 0.9766 | 0.9635 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9453.121 | 1.0057 | 1.0088 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9453.121 | 0.8838 | 0.8168 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9453.121 | 0.3263 | -0.1628 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9453.121 | 0.0744 | -0.7348 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9453.121 | 0.0607 | -0.7737 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9453.121 | 0.0378 | -0.8432 | 1.2860 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 9453.121 | 0.0022 | -0.9827 | 1.2860 |